Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)’ to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) in the United States. This study aims to enroll approximately 1,000 patients across 45 sites, focusing on identifying eHC in a specific patient population, which could have significant implications for treatment approaches in resistant hypertension.
The study is non-interventional, meaning it does not involve testing new drugs or treatments. Instead, it focuses on screening and diagnostic procedures to identify eHC in patients with rHTN. This involves a series of visits for screening, lab tests, and diagnostic imaging.
This observational study follows a cohort model with a cross-sectional time perspective. It involves no allocation or intervention model, as it is primarily focused on assessing the prevalence of a condition rather than testing a treatment.
The study began on March 28, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 4, 2025, indicating ongoing recruitment and data collection.
The outcomes of this study could influence Corcept Therapeutics’ market position by highlighting new opportunities in the treatment of resistant hypertension. Positive findings might boost investor confidence and impact stock performance, especially if the study identifies a significant prevalence of eHC, suggesting a potential market for targeted therapies. Competitors in the hypertension treatment space may also be affected as the study could shift focus towards more personalized treatment approaches.
The study is currently ongoing, with further details available on the ClinicalTrials portal.